AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 61 min read$CYTK

Malik Fady Ibraham sold $215K of CYTK

Malik Fady Ibraham (EVP Research & Development) sold 3,500 shares of CYTOKINETICS INC (CYTK) at $61.38 ($0.21M total) on 2026-10-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Malik Fady Ibraham
Published Oct 6, 2026, 8:25 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 8:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CYTK
Bearish
high confidence
Mentioned
$CYTK
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CYTKBearishLow
01

Why it matters

The disclosed sale adds transparency and may cause a modest short‑term dip, but the overall ownership remains strong.

02

Market read

A small insider sell reported for the first time; limited trading impact but worth noting for short‑term sentiment.

03

What to watch

The insider retains a large stake (over 150k shares) and the sale price was above recent market levels.

Relevance 3/10Novelty 3/10Timing: same-day filing

Background

Form 4 filings disclose insider transactions; a 10b5‑1 plan indicates pre‑arranged sales to avoid timing concerns.

Company-level read

Ticker impact

$CYTKBearishHigh confidence
Context

SEC Form 4 shows EVP R&D Malik Fady Ibraham sold 3,500 shares for $214,830 via a 10b5-1 plan.

Expected impact

potential slight downward pressure as the market prices the insider sell.

Evidence & confidence

The sale represents ~0.2% of the insider's post‑transaction holdings and is disclosed for the first time.

Market effects

Sector

Minimal impact on the broader biotech sector; insider activity is company‑specific.

Regional

No regional effect; the filing is U.S. SEC‑based only.

Global

Limited global relevance; only affects CYTK investors.

Counterpoint

What could challenge this read

The sale could be routine execution of a pre‑arranged plan, not a bearish signal.

Key entities

  • Company
    CytoKinetics Inc.

    Biotech firm developing cell‑based therapies.

  • Person
    Malik Fady Ibraham

    EVP of Research & Development at CytoKinetics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CYTK insider trading history →

Related articles

OCT 13
$CYTKHigh

Cytokinetics Highlights Exercise Capacity, Responder Data For Aficamten In NHCM At HFSA 2026

Cytokinetics (CYTK) presented data from the ACACIA-HCM trial at the HFSA 2026 meeting, showing aficamten improved exercise performance and clinical outcomes in non-obstructive HCM patients. The drug demonstrated significant benefits in exercise capacity, symptom relief, and safety, with 53% of patients showing improvements across multiple domains. CYTK reported a Q2 2026 net loss of $198.8M and $25.3M in aficamten revenue, with cash reserves of $1.7B.

rttnews.com2 min
OCT 12
$CYTKMed

Cytokinetics presents additional aficamten data from trial

Cytokinetics (CYTK) presented additional data from its ACACIA-HCM trial at the Heart Failure Society of America Annual Scientific Meeting. Aficamten showed statistically significant improvements in exercise performance and clinical response in patients with non-obstructive hypertrophic cardiomyopathy. The company plans to submit a supplemental New Drug Application to the FDA this quarter for this indication.

uk.investing.com1 min
OCT 12
$CYTKMed

Serious heart failure events affected 4.7% taking aficamten, versus 1.2% on placebo.

Cytokinetics (CYTK) presented additional data from the ACACIA-HCM trial at the HFSA Annual Scientific Meeting. The study showed aficamten improved exercise performance and safety in non-obstructive HCM patients. Serious heart failure events occurred in 4.7% of aficamten patients vs. 1.2% on placebo. The company plans to submit a supplemental New Drug Application to the FDA this quarter.

stocktitan.net4 min